Advances in pediatric heart transplantation

Current Opinion in Pediatrics

Volumn 18, Issue 5, 2006, Pages 512-517

  Schowengerdt, Kenneth O ^a,b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac; Immunosuppression; Transplant; Vasculopathy

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PRAVASTATIN; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

B CELL LYMPHOMA; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; DISEASE COURSE; GRAFT FAILURE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LYMPHOPROLIFERATIVE DISEASE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

CHILD; HEART TRANSPLANTATION; HUMANS;

EID: 33748754528     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000245351.37713.13     Document Type: Review

References (47)

1. Boucek MM, Edwards LB, Keck BM, et al. Registry of the International Society for Heart and Lung Transplantation: 8th official pediatric report - 2005. J Heart Lung Transplant 2005; 24:968-982. This is the most recent pediatric registry report from the ISHLT outlining the cumulative international experience for pediatric thoracic organ transplantation. It summarizes survival, modes of immunosuppression, risk factors for mortality, causes of death, and specific complications.
2. Taylor DO, Edwards LB, Mohacsi PJ, et al. Registry of the International Society for Heart and Lung Transplantation: 20th official adult heart transplant report - 2003. J Heart Lung Transplant 2003; 22:625-635.
3. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant 1992; 11:S38-S44.
4. Eisen H, Kobashigawa J, Starling RC, et al. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors. Transplant Proc 2005; 37 (4 Suppl):4S-17S. This is a recent review that provides background on our current understanding of cardiac allograft vasculopathy as well as the effects of proliferation signal inhibitors on the progression of this entity in adult patients.
5. Pinney SP, Mancini D. Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. Curr Opin Cardiol 2004; 19:170-176.
6. Caforio ALP, Tona F, Belloni Fortina A, et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant 2004; 4:962-970.
7. Valentine HA. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 2004; 23 (5 Suppl):S187-S193.
8. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261:3561-3566.
9. Pahl E, Naftel DC, Kuhn MA, et al. The impact and outcome of transplant coronary artery disease in a pediatric population: a 9-year multiinstitutional study. J Heart Lung Transplant 2005; 24:645-651. This multiinstitutional study is the largest pediatric study to date evaluating the impact and outcome of transplant coronary artery disease. Unlike the adult studies, in which intravascular ultrasound is commonly used to evaluate CAV, the diagnosis of vasculopathy was based upon angiographic review. Given the characteristics of allograft vasculopathy and the limitations of angiography, the 17% incidence of abnormalities found at 5 years may be an underestimate.
10. Kapadia SR, Ziada KM, L'Allier PL, et al. Intravascular ultrasound imaging after cardiac transplantation: advantage of multivessel imaging. J Heart Lung Transplant 2000; 19:167-172.
11. Tham EBC, Yeung AC, Cheng CWB, et al. Experience of percutaneous coronary intervention in the management of pediatric coronary vasculopathy. J Heart Lung Transplant 2005; 24:769-773. Reports of interventional management of CAV in pediatric recipients are limited and this series, although small, provides added information as to its utility and short and long-term results.
12. Kahan BD, Rajogopalan PR, Hall M, for the United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric antiinterleukin-2- receptor monoclonal antibody. Transplantation 1999; 67:276-284.
13. Nashan B, Moore R, Amlot P, et al., for the CHIB 201 International Study Group. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350:1193-1198.
14. Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005; 24:1297-1304. This prospective, randomized trial of the IL-2 receptor monoclonal antibody in adult heart transplant patients demonstrated it to be well tolerated, and indicated a trend towards a longer time to the first rejection episode.
15. Rosenberg BP, Vriesendorp AE, Drazner MH, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 2005; 24:1327-1331.
16. Ford KA, Cale CM, Rees PG, et al. Initial data on basiliximab in critically ill children undergoing heart transplantation. J Heart Lung Transplant 2005; 24:1284-1288. This pediatric study evaluated the utility of the IL-2 receptor blocker, basiliximab, in critically ill patients after transplantation. No adverse effects were reported, and its use allowed the delayed introduction of calcineurin inhibitors to minimize renal toxicity in high-risk patients.
17. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940.
18. Kahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991; 52:185-191.
19. Lobach NE, Pollock-BarZiv SM, West LJ, Dipchand AI. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant 2005; 24:184-189. Limited numbers of reports regarding the use of sirolimus in pediatric heart transplant recipients exist, and this recent single-center experience supports its utility in the treatment of rejection, preserving renal function, and minimizing calcineurin inhibitor side-effects.
20. Balfour IC, Srun SW, Wood EG, Belsha CW. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant 2006; 25:518-522. This single-center pediatric study evaluated renal function in transplant recipients before and after the introduction of sirolimus to their immunosuppressive regimen, allowing a reduction in dose or the cessation of calcineurin inhibitors. Renal function improved within 30 days, without a significant increase in rejection.
21. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac transplant recipients with chronic renal failure. Transplantation 2004; 77:568-573.
22. Trosch F, Rothenburger M, Schneider M, et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 2004; 52:163-168.
23. Penson MG, Winter WE, Fricker FJ, et al. Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. J Heart Lung Transplant 1999; 18:707-713.
24. Law YM, Yim R, Agatisa P, et al. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens. J Heart Lung Transplant 2006; 25:276-282.
25. Eich D, Thompson JA, Ko DJ, et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant 1991; 10:45-49.
26. Kapadia SR, Nissen SE, Ziada KM, et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study. J Am Coll Cardiol 2001; 38:206-213.
27. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621-627.
28. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005; 24:1736-1740. The adult literature now includes long-term follow-up data regarding statin use in heart transplant patients. This report is important in that the initial survival benefit and decreased incidence of CAV in the pravastatin-treated group continued over time.
29. Penson MG, Fricker FJ, Thompson JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001; 20:611-618.
30. Seipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. J Heart Lung Transplant 2004; 23:317-322.
31. Chin C, Gamberg P, Miller J, et al. Efficacy and safety of atorvastatin after pediatric heart transplantation. J Heart Lung Transplant 2002; 21:1213-1217.
32. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant 2005; 24:63-66. Although there are a number of studies in the adult literature describing the beneficial effects of statin drugs in the prevention of CAV, this is the first pediatric study to report a reduction of CAV in patients receiving pravastatin. Additional large-scale pediatric studies are required to evaluate the long-term benefits further.
33. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399-1402.
34. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7:687-692.
35. Nalesnik MA. Clinical and pathological features of posttransplant lymphoproliferative disorders (PTLD). Springer Semin Immunopathol 1998; 20:325-342.
36. Harris NL, Swerdlow SH, Frizzera G, Knowles DM. Posttransplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumors. Lyon: IARC Press; 2001. pp. 264-269.
37. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1986; 45:719-727.
38. Zangwill SD, Hsu DT, Kichuk MR, et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant 1998; 17:1161-1166.
39. Webber SA. Posttransplant lymphoproliferative disorders: a preventable complication of solid organ transplantation? Pediatr Transplant 1999; 3:95-99.
40. Mendoza F, Kunitake H, Laks H, Odim J. Posttransplant lymphoproliferative disorder following pediatric heart transplantation. Pediatr Transplant 2006; 10:60-66.
41. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59:524-529.
42. Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999; 68:997-1003.
43. Sokal EM, Antunes H, Begun D, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64:1438-1442.
44. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after pediatric heart transplantation: a multiinstitutional study. Lancet 2006; 367:233-239. This represents the largest pediatric study to date (1184 heart transplant recipients) providing valuable information regarding the modes of presentation, pathology, treatment, and outcomes of PTLD.
45. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108:48-53.
46. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary heart disease at 2 years. A randomized clinical trial. Circulation 2004; 110:2694-2700.
47. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003; 349:847-858.